Mancini Marianna

VKTX COO Mancini sells 57,661 shares for $1.9M as stock falls -25.1% from 52-week high

Marianna Mancini, Chief Operating Officer of Viking Therapeutics, executed 4 separate sales totaling 57,661 shares for $1,901,405.31 on 2026-01-05, reducing her holdings by 12.4% to 409,190 shares post-transaction. The blended average price of $32.98 occurs as the stock trades at $32.14, down -25.1% from its 52-week high of $42.89 and down -16.6% over the prior 30 days. Her same-ticker history at VKTX shows mixed timing outcomes: three of five prior sales were well-timed at the 90-day mark (stock subsequently fell), though two prior sales on 2024-07-30 saw subsequent 30-day and 90-day gains. The company posted $-90,787,000 net loss most recently with zero revenue, suggesting ongoing operational strain. The scale of this insider reduction (57.7K shares) warrants attention given the company's unprofitable status and the stock's recent retreat, though the transaction timing relative to price action does not yet constitute a clear reversal signal.

COO Marianna Mancini sold 54,215 shares for $2,317,599.12 at avg $42.75 on 2025-01-06; stock now -55.0% from 52-week high.

Mancini executed 2 separate sales totaling 54,215 shares for $2,317,599.12, reducing her holdings by 12.7% from 428,349 to 374,134 shares. The timing context is relevant: her prior 5 same-ticker sales at VKTX produced mixed returns (3 of 5 well-timed at the 90-day mark), but her cross-ticker track record shows a 71.43% well-timed rate across 7 prior sells with a -11.4% average 90-day return. However, the company context is material—VKTX is unprofitable (net income $-24,940,000.00 in the latest quarter), generated zero revenue in the latest quarter, and the stock has fallen -55.0% from its 52-week high of $94.50 and -36.2% over the past 90 days. The sale prices of $42.69 and $43.32 occurred as the stock approached its current $42.53 price, placing the sales near the lower end of recent trading. This transaction reflects a meaningful reduction in equity exposure by a senior executive during a period of significant drawdown and ongoing operating losses.

COO Mancini sells 18,026 shares at blended $57.13; prior 5 sells at VKTX all well-timed (90d: -18.5% to -22.2%)

Mancini Marianna, Chief Operating Officer of Viking Therapeutics, executed 2 separate sales totaling 18,026 shares for $1,029,911.96 on 2024-07-30, reducing her holdings by 4.7%. Notably, her 5 prior open-market sales at VKTX (all on 2024-05-01) exhibited a consistent pattern of well-timed exits, with 90-day post-sale declines ranging from -18.5% to -22.2%, and a 100% well-timed rate at the 90-day mark. The company is unprofitable with $-22,250,000.00 in net income over its most recent full fiscal year and zero quarterly revenue in the latest period. The stock is currently -39.7% from its 52-week high of $94.50, having declined -24.8% over the past 90 days.